Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
The German pharmaceutical-and-agricultural group said that the deal aims to complement its ophthalmology pipeline.
Where News Facts Matter
Flash News
Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion
With Indiana, Trump asserts his grip on the GOP
‘The Kamala Harris problem’: Vance’s 2028 hopes hinge on Trump, Iowa Republicans say
Model Alex Consani Frees the Nipple in Sheer Look
Novo Nordisk (NVO) Q1 2026 earnings: Wegovy sales jump
No 1970s but oil shock still hits consumers, businesses
Russian attacks kill 27 in Ukraine before proposed rival ceasefires
From Beijing to Berlin: Chinese EVs turn heads as brands eye European markets
Entrepreneurs Flocked to Colorado. Now Red Tape Is Driving Some Away.
Kentucky Derby’s most remarkable fan makes 80th straight race
Wednesday, May 06, 2026